spacer
home > ict > winter 2009 > chain reactions
PUBLICATIONS
International Clinical Trials

Chain Reactions

 

Management of cold chain clinical supplies presents sponsor companies with significant logistical challenges, especially considering the global nature of distribution to many less developed regions and emerging markets. When investigational products are shipped, supplies are subject to various factors which may influence the way in which temperature-controlled shipping systems may operate. These variables include a myriad of external temperature ranges, supply routes, transit time, and availability of stability data and people.

The nature of clinical trial shipments means that they are exposed to more risks than commercial shipments due to their urgency, diverse destinations, shipping methodologies or routes and variable shipment quantities. However, the goal still remains to ensure a consistent flow of material arriving at the site in a condition which is fit for its intended use.

When contemplating cold chain logistics, there are a number of elements to take into consideration:

  • Packaging for maintenance of temperature control – active and passive shipping systems
  • Use of monitoring devices
  • Courier selection and transit time
  • Planning for deviations

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jonathan Calderwood is the Global Marketing Manager for Almac Clinical Services (Almac Group). He was educated in Queen’s University, gaining a BSc in Biochemistry, and he holds a Post Graduate Diploma in Computer Science and in Marketing, and is a member of the Chartered Institute of Marketing. Jonathan has extensive experience in clinical trial supply production and project management, as well as in the business development field.

spacer
Jonathan Calderwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nordic Capital acquires specialty pharmaceutical company Advanz Pharma in deal worth ~$846 million

The acquisition will bring significant investment and expertise to help fuel ADVANZ PHARMA’s growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to critical medicines globally.
More info >>

White Papers

High-tech Packaging for High-tech Medicine

West Pharmaceutical Services, Inc.

As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement